Curr Opin Cardiol. 2021 May 14. doi: 10.1097/HCO.0000000000000884. Online ahead of print.
ABSTRACT
PURPOSE OF REVIEW: A significant number of patients with mitral valve disease are at high to prohibitive risk for surgical repair or replacement. Transcatheter mitral valve interventions have evolved over the last few years. We review the recent growing evidence on transcatheter mitral valve replacement (TMVR).
RECENT FINDINGS: Tendyne is the first TMVR device commercially approved in Europe. All TMVR systems remain under investigation in the United States. Several early studies have reported the feasibility and safety outcomes for TMVR implanted via transapical or transseptal approach. TMVR using balloon expandable valve for degenerated bioprosthetic valves, surgical rings and mitral annular calcification appears feasible in selected patients.
SUMMARY: Early experience with TMVR systems is promising. Larger ongoing studies will help understand longer term outcomes and offer insights into patient selection.
PMID:33990479 | DOI:10.1097/HCO.0000000000000884